Clinical Trial

TMS-related Measures as Biomarker of Cognitive Impairment in PD

Study acronym: SAI-PD22
Recruiting
View on ClinicalTrials.gov →
Summary
The goal of the present study is to explore the diagnostic and prognostic value of neurophysiological biomarkers obtained through paired-pulse Transcranial Magnetic Stimulation (TMS) techniques in individuals affected by Parkinson's disease (PD) with and without cognitive decline. The main questions it aims to answer are: * TMS measures of cortical excitability are able to distinguish between PD patients cognitively normal, PD-Mild Cognitive Impairment (PD-MCI) and PD-Dementia (PD-D)? * TMS measures of cortical excitability are able to predict progression of PD patient cognitive status from cognitively normal to PD-MCI and PD-D?
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-02-14; most recent amendment 2025-12-16.
Status change: Not Yet Recruiting → Recruiting 2025-12-16
Status change: Recruiting → Not Yet Recruiting 2025-02-24
Trial Details
NCT Number NCT06835595
Lead Sponsor Azienda Sanitaria Universitaria Integrata del Trentino
Conditions Parkinson Disease
Enrollment 52 participants
Start Date 2025-09-10
Primary Completion 2029-01-01 (estimated)
Study Completion 2029-01-01 (estimated)
Updated on ClinicalTrials.gov 2025-12-22